Modulation of cell metabolic pathways and oxidative stress signaling contribute to acquired melphalan resistance in multiple myeloma cells

PloS One
Kamila Anna ZubGeir Slupphaug

Abstract

Alkylating agents are widely used chemotherapeutics in the treatment of many cancers, including leukemia, lymphoma, multiple myeloma, sarcoma, lung, breast and ovarian cancer. Melphalan is the most commonly used chemotherapeutic agent against multiple myeloma. However, despite a 70-80% initial response rate, virtually all patients eventually relapse due to the emergence of drug-resistant tumour cells. By using global proteomic and transcriptomic profiling on melphalan sensitive and resistant RPMI8226 cell lines followed by functional assays, we discovered changes in cellular processes and pathways not previously associated with melphalan resistance in multiple myeloma cells, including a metabolic switch conforming to the Warburg effect (aerobic glycolysis), and an elevated oxidative stress response mediated by VEGF/IL8-signaling. In addition, up-regulated aldo-keto reductase levels of the AKR1C family involved in prostaglandin synthesis contribute to the resistant phenotype. Finally, selected metabolic and oxidative stress response enzymes were targeted by inhibitors, several of which displayed a selective cytotoxicity against the melphalan-resistant cells and should be further explored to elucidate their potential to overcome ...Continue Reading

References

Jan 1, 1982·Cancer Chemotherapy and Pharmacology·A E AhmedJ Costanzi
Dec 1, 1994·Mutation Research·L F Povirk, D E Shuker
Mar 1, 1996·Analytical Chemistry·A ShevchenkoM Mann
Mar 3, 1997·FEBS Letters·A GormanT G Cotter
Feb 3, 1999·Proceedings of the National Academy of Sciences of the United States of America·G A BrooksC E Butz
Mar 27, 2001·Gastroenterology·M B SchneiderP M Pour
Feb 21, 2002·Trends in Endocrinology and Metabolism : TEM·David R Plas, Craig B Thompson
Jun 22, 2002·Chemico-biological Interactions·Joost RothbarthGerard J Mulder
May 10, 2003·Pflügers Archiv : European journal of physiology·Andrew P Halestrap, David Meredith
Feb 24, 1956·Science·O WARBURG
Sep 27, 2003·The Biochemical Journal·Marc OuelletM David Percival
Oct 6, 2004·Genome Biology·Robert C GentlemanJianhua Zhang
Nov 16, 2004·International Journal of Hematology·Marcela OanceaAlexandru Almasan
Mar 10, 2005·The Journal of Biological Chemistry·Yvonne KumaAna Cuenda
Aug 30, 2005·Experimental Gerontology·Vladimir N AnisimovClaudio Franceschi
Jan 25, 2006·Molecular Cancer Therapeutics·Tadashi IkegamiBernard Bouscarel
Apr 11, 2006·Molecular Cell·Dos D SarbassovDavid M Sabatini
May 2, 2006·Statistical Applications in Genetics and Molecular Biology·Gordon K Smyth
Aug 17, 2006·Blood·Ludivine LeseuxChristine Bezombes
Feb 17, 2007·The Biochemical Journal·Severine I GharbiMichael D Waterfield
Jun 1, 2007·Archives of Biochemistry and Biophysics·Trevor M Penning, Jason E Drury
Jul 16, 2008·Analytical and Bioanalytical Chemistry·Dalia Mohamed, Michael Linscheid
Oct 23, 2008·Genetics in Medicine : Official Journal of the American College of Medical Genetics·Ralph J DeBerardinis
Nov 5, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·David J J Waugh, Catherine Wilson
Apr 7, 2009·British Journal of Haematology·Sagar Lonial, Jamie Cavenagh
May 21, 2009·Seminars in Musculoskeletal Radiology·Andrea Baur-Melnyk, Maximilian F Reiser
Jun 23, 2009·Lancet·Marc S RaabKenneth C Anderson
Sep 1, 2009·Clinical Lymphoma & Myeloma·Robert A Kyle, S Vincent Rajkumar
Oct 29, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Chi V DangPing Gao
Nov 26, 2009·Cancer Research·Danielle N YardeWilliam S Dalton
Oct 16, 2010·Cancer Prevention Research·Andrea DecensiSara Gandini

❮ Previous
Next ❯

Citations

Jul 6, 2016·Frontiers in Endocrinology·Carolyne FalankMichaela R Reagan
Jan 15, 2017·Journal of Hematology & Oncology·Zhimin GuFenghuang Zhan
Apr 19, 2017·Oncotarget·Marta IrigoyenEdurne Berra
Sep 2, 2017·Current Osteoporosis Reports·Cristina PanaroniNoopur S Raje
Jan 1, 2018·Cancer Chemotherapy and Pharmacology·Olexandr FedorchukLarysa Skivka
Apr 18, 2018·International Journal of Molecular Sciences·Chaima El ArfaniEline Menu
Aug 29, 2019·International Journal of Molecular Sciences·Anna C Beielstein, Christian P Pallasch
Nov 13, 2019·Molecular Cancer·Xinming JingYongqian Shu
Dec 18, 2020·International Journal of Molecular Sciences·Aleksandra KlembaClaudine Kieda
May 21, 2021·Journal of Proteome Research·David C KoomenKenneth H Shain
Jun 3, 2021·Cancers·Mélody CaillotBrigitte Sola
Jan 1, 2020·Expert Review of Precision Medicine and Drug Development·Matthew HoKenneth C Anderson

❮ Previous
Next ❯

Methods Mentioned

BETA
Assay
GTPase
NMR
proteomic profiling

Software Mentioned

Mascot
lumi
GraphPad Prism
Limma
R
Bioplex manager
Bioconductor package
MaxQuant
Ingenuity Pathway Analysis ( IPA )
Bioconductor package `

Related Concepts

Related Feeds

Cancer Metabolism

In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Breast Cancer: BRCA1 & BRCA2

Mutations involving BRCA1, found on chromosome 17, and BRCA2, found on chromosome 13, increase the risk for specific cancers, such as breast cancer. Discover the last research on breast cancer BRCA1 and BRCA2 here.

Cancer Metabolic Reprogramming (Keystone)

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.

Cancer Metabolic Reprogramming

Cancer metabolic reprogramming is important for the rapid growth and proliferation of cancer cells. Cancer cells have the ability to change their metabolic demands depending on their environment, regulated by the activation of oncogenes or loss of tumor suppressor genes. Here is the latest research on cancer metabolic reprogramming.

Cancer Metabolism: Therapeutic Targets

Targeting the mechanisms by which cancer cells acquire energy for metabolic needs is a therapeutic target. Discover the latest research on cancer metabolism and therapeutic targets.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis